FDA rebuffs long-acting Zyprexa
Eli Lilly and Co. has been rejected in its attempt to win approval for a long-acting, injectible version of its best-selling drug, Zyprexa. The U.S. Food and Drug Administration told the Indianapolis-based drugmaker in a “not approvable letter” that it needs more information on the medicine’s major side effect, excessive sleepiness, the Indianapolis drugmaker announced […]